USE OF PROTEIN KINASE C DELTA (PKCD) INHIBITORS TO TREAT DIABETES, OBESITY, AND HEPATIC STEATOSIS

摘要

Described are methods of improving insulin sensitivity, and treating fatty liver disease (including non-alcoholic steatohepatitis (NASH)), by administering specific inhibitors of PKC delta.